BioArctic Past Earnings Performance
Past criteria checks 0/6
BioArctic's earnings have been declining at an average annual rate of -7.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 14% per year.
Key information
-7.1%
Earnings growth rate
-7.0%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 14.0% |
| Return on equity | -25.3% |
| Net Margin | -139.3% |
| Next Earnings Update | 13 Feb 2025 |
Recent past performance updates
Recent updates
Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Nov 27
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sep 01Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
Aug 15Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade
May 06Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth
Mar 13Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher
Nov 30We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn
Sep 16Revenue & Expenses Breakdown
How BioArctic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 167 | -233 | 220 | 94 |
| 30 Jun 24 | 299 | -88 | 232 | 58 |
| 31 Mar 24 | 252 | -122 | 258 | 16 |
| 31 Dec 23 | 616 | 229 | 251 | 0 |
| 30 Sep 23 | 607 | 259 | 176 | 121 |
| 30 Jun 23 | 617 | 270 | 182 | 88 |
| 31 Mar 23 | 619 | 327 | 151 | 47 |
| 31 Dec 22 | 229 | -11 | 149 | 0 |
| 30 Sep 22 | 232 | 28 | 131 | 0 |
| 30 Jun 22 | 18 | -147 | 110 | 0 |
| 31 Mar 22 | 21 | -135 | 104 | 0 |
| 31 Dec 21 | 26 | -120 | 97 | 0 |
| 30 Sep 21 | 30 | -114 | 95 | 0 |
| 30 Jun 21 | 37 | -97 | 89 | 0 |
| 31 Mar 21 | 34 | -101 | 87 | 0 |
| 31 Dec 20 | 65 | -69 | 86 | 0 |
| 30 Sep 20 | 84 | -72 | 87 | 0 |
| 30 Jun 20 | 93 | -60 | 87 | 0 |
| 31 Mar 20 | 252 | 78 | 94 | 0 |
| 31 Dec 19 | 283 | 88 | 91 | 0 |
| 30 Sep 19 | 779 | 441 | 101 | 0 |
| 30 Jun 19 | 852 | 475 | 101 | 0 |
| 31 Mar 19 | 729 | 380 | 91 | 0 |
| 31 Dec 18 | 722 | 382 | 89 | 0 |
| 30 Sep 18 | 257 | 58 | 78 | 0 |
| 30 Jun 18 | 197 | 32 | 77 | 0 |
| 31 Mar 18 | 194 | 29 | 83 | -17 |
| 31 Dec 17 | 157 | 15 | 69 | 0 |
| 30 Sep 17 | 193 | 78 | 54 | 22 |
| 30 Jun 17 | 160 | 71 | 41 | 31 |
| 31 Mar 17 | 127 | 64 | 17 | 60 |
| 31 Dec 16 | 106 | 58 | 16 | 54 |
| 31 Dec 15 | 42 | 4 | 6 | 38 |
Quality Earnings: BIOA B is currently unprofitable.
Growing Profit Margin: BIOA B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOA B is unprofitable, and losses have increased over the past 5 years at a rate of 7.1% per year.
Accelerating Growth: Unable to compare BIOA B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOA B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: BIOA B has a negative Return on Equity (-25.35%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 01:24 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioArctic AB (publ) is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Patrik Ling | DNB Markets |
| Rajan Sharma | Goldman Sachs |